Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Avanti Biosciences Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is located in 1 distinct art unit. This indicates a focused prosecution effort within the biotechnology sector. The presence of 1 distinct art unit allows the company to concentrate its legal resources on the specific requirements of a single technical group at the USPTO.
The busiest examiner for the company is NEAGU, IRINA, who is handling 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the firm's current patent activity is concentrated. This single examiner, NEAGU, IRINA, is responsible for the 1 pending office action that constitutes the entire active portfolio. The outcome of the pending matter is determined by the specific examination style of this 1 distinct examiner. Practitioners should note that the 1 distinct examiner, NEAGU, IRINA, represents the sole point of contact for the company's immediate prosecution needs, simplifying the overall management of the active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.8% | +57.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576176 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | NEAGU, IRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18576176 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576176 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | NEAGU, IRINA | 1629 | §102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial